New insights into gene therapy for CMT1A
CMT type 1A (CMT1A) is the most common form of Charcot-Marie-Tooth disease. Its cause is well understood, which is exactly why it is one of the most promising targets for gene therapy.
The genetic cause
In CMT1A there is a duplication of the PMP22 gene on chromosome 17. As a result, the body produces too much of the PMP22 protein. This protein is a building block of myelin, the insulating layer around the peripheral nerves. Too much PMP22 disrupts this insulation, so nerve signals become slower and weaker — leading to muscle weakness and loss of sensation.
Why gene therapy is promising
Because the problem is an excess of one well-known protein, the strategy is clear: bring the amount of PMP22 back to a normal level. Researchers are exploring several techniques:
- Antisense oligonucleotides (ASOs) — short pieces of genetic material that reduce the production of PMP22.
- RNA interference (siRNA) — molecules that break down the PMP22 messenger RNA before the protein is made.
- Gene-targeted approaches that dampen the activity of the duplicated gene.
What the research shows
In animal models, lowering PMP22 leads to better myelin formation and recovery of nerve function. Several candidates are moving from the laboratory into the first clinical studies in humans. That is an important milestone, but it also means this is still research: at present there is no approved gene therapy for CMT1A.
What does this mean for patients?
This progress gives realistic hope that a treatment addressing the cause — rather than only the symptoms — may become available in the future. At the same time, patience is needed: it often takes years of careful studies to go from promising research to a safe, widely available therapy.
Do you have questions about your own situation or about taking part in research? Discuss this with your neurologist or a specialised CMT centre.
This article is for information only and does not replace medical advice.
